Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new systematic review finds GLP-1 receptor agonists can drive weight loss of up to 24% in adults with obesity who don't have diabetes — levels once only seen with bariatric surgery. Newer multiagonist drugs like amycretin and retatrutide are leading the pack, but experts warn that coverage gaps and political will remain major barriers to patient access.
A sweeping updated systematic review published in Annals of Internal Medicine confirms that GLP-1 receptor agonists deliver substantial weight loss in adults with overweight or obesity who don't have diabetes — and the newer generation of drugs is pushing those numbers even higher. Analyzing 38 randomized controlled trials with over 25,000 participants, researchers found that weight loss varies significantly across agents, with emerging multiagonist therapies outperforming older options.
The review also included the first long-term head-to-head trial data, showing tirzepatide and cagrilintide-semaglutide outperform semaglutide, while semaglutide beats liraglutide. Experts caution, however, that varying treatment durations make direct comparisons tricky, and greater weight loss didn't always translate to proportionally better cardiometabolic outcomes like blood pressure improvement.
By the Numbers:
Why it matters: These drugs are now achieving weight loss comparable to bariatric surgery, giving clinicians a growing toolkit to personalize obesity treatment. But the real-world bottleneck isn't efficacy — it's access. Coverage remains limited due to constrained healthcare budgets and policymakers not yet fully convinced of long-term benefits, turning what should be a medical decision into a political one.
